Zepbound and Anesthesia: What You Need to Know Before Surgery

Why Anesthesia and Tirzepatide Are a Concerning Combination

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for chronic weight management. Its gastric-slowing effects are well-documented in human pharmacodynamic studies, and those effects do not simply "wear off" overnight. A patient who takes their weekly Zepbound dose on Sunday and goes to the operating room on Thursday may still have significantly delayed gastric emptying, even after following standard nil-per-os (NPO) fasting instructions.

Aspiration of gastric contents during induction of anesthesia or sedation can cause chemical pneumonitis, aspiration pneumonia, and in severe cases, death. Because GLP-1 receptor agonists are now prescribed to tens of millions of patients in the United States, anesthesiologists began encountering unexpected full stomachs in patients who had fasted correctly, and the profession responded with formal guidance.

The Mechanism: GLP-1 Receptor Activation and the Stomach

Both GLP-1 and GIP receptors are expressed in the enteric nervous system. Activation of the GLP-1 receptor in particular suppresses pyloric tone and reduces antral contractility, directly slowing the transit of solid and liquid contents from the stomach into the duodenum. A 2023 scintigraphy study published in Diabetes, Obesity and Metabolism showed that GLP-1 receptor agonists delay the half-time of gastric solid emptying by a mean of approximately 116 minutes compared to placebo, an effect large enough to be clinically meaningful under anesthesia. [1]

Tirzepatide adds dual-receptor activity. Its affinity for the GIP receptor modulates GLP-1 signaling in a way that may amplify certain gastrointestinal effects. The SURMOUNT-1 trial (N=2,539) documented nausea, vomiting, and diarrhea in 18-44% of tirzepatide patients across dose groups, reflecting the drug's substantial gastrointestinal activity. [2] Those GI effects are a clinical proxy for the same enteric pathway that slows gastric emptying.

The Aspiration Risk: What the Cases Tell Us

Case reports of patients on GLP-1 agonists presenting with full stomachs despite 8-12 hours of fasting began appearing in peer-reviewed anesthesia literature in 2022 and 2023. A letter in Anesthesiology (2023) described patients on semaglutide with solid food visible in the stomach on pre-procedural gastric ultrasound despite standard fasting. [3] Tirzepatide shares the same mechanism and, at higher doses, may produce equivalent or greater gastric slowing.

The FDA-approved Zepbound Prescribing Information notes nausea, vomiting, and delayed gastric emptying as recognized pharmacodynamic effects. [4] These effects are not idiosyncratic; they are expected at therapeutic doses.

Official Guidelines: What the ASA Now Recommends

The American Society of Anesthesiologists issued a formal consensus-based guidance document in June 2023 that directly addresses GLP-1 receptor agonists before surgery. That document was endorsed by the ASA's Committee on Patient Safety and Quality and is the authoritative current standard in U.S. Anesthesia practice. [5]

The Core Hold Recommendation

The ASA recommends the following for patients on GLP-1 receptor agonists scheduled for elective procedures:

• Weekly-dosed agents (semaglutide, tirzepatide): hold for 1 week before the procedure.
• Daily-dosed agents (liraglutide, exenatide): hold for 1 day before the procedure.

Tirzepatide's approved weekly dosing schedule places it squarely in the one-week hold category. The guidance document states: "If GLP-1 agonist cannot be held... Consider doing a point-of-care gastric ultrasound to assess gastric volume... If the gastric ultrasound is not available... Consider patient to have a 'full stomach' and manage with rapid sequence induction." [5]

Why Standard Fasting Is Not Enough on Its Own

The standard NPO guidelines from the ASA call for no solid food for 8 hours, no non-clear liquids for 6 hours, and no clear liquids for 2 hours before elective anesthesia. [6] Those intervals were derived from populations with normal gastric motility. A patient whose gastric emptying has been slowed by 116 or more minutes by a GLP-1 agonist does not fit that population. Following NPO rules without also holding the medication may still leave residual solid content in the stomach.

The HealthRX clinical team uses a practical three-step perioperative checklist for patients prescribed Zepbound:

1. At the time of procedure scheduling: Notify the anesthesiologist and surgical coordinator of Zepbound use and current dose.
2. One week before the procedure: Take the last Zepbound dose no later than 7 days prior to the procedure date. Do not take the next scheduled weekly dose.
3. Day of procedure: Confirm with the anesthesia team that Zepbound was held; follow all NPO instructions as instructed. If the hold was not completed, tell the team immediately so rapid-sequence induction can be planned.

Tirzepatide's Pharmacokinetics and Why One Week Matters

Tirzepatide has a half-life of approximately 5 days. Per the FDA-approved prescribing label, it reaches steady-state plasma concentrations after 4 weeks of weekly dosing. [4] A single missed weekly dose drops plasma levels by roughly 50% over 5 days, but pharmacodynamic effects on the gut may persist beyond what plasma levels alone predict.

Steady-State Accumulation and Tissue Effects

At steady state, tirzepatide levels are approximately 2-fold higher than after a single dose. This accumulation means that by the time a patient has been on Zepbound for 4 or more weeks, the drug's gastrointestinal effects are at their peak. Holding for one week allows plasma concentration to fall by about 50%, which is why the ASA chose this interval. It is not a perfect washout; it is a pragmatic risk reduction for elective cases.

For procedures that cannot be postponed, a full seven-day hold is not possible. In those circumstances, the ASA's guidance defaults to assuming a full stomach and adjusting the anesthetic plan accordingly, regardless of how long the patient has fasted.

Dose-Dependent Effects on Gastric Emptying

Tirzepatide is initiated at 2.5 mg weekly and titrated up to a maximum of 15 mg weekly. Gastric emptying delay appears to be dose-related for GLP-1 agonists as a class. A pharmacodynamic study in Diabetes Care (2022) confirmed that higher doses of GLP-1 receptor agonists produce greater reductions in gastric emptying rates for solid meals. [7] Patients on 10 mg or 15 mg tirzepatide likely carry a higher residual gastric volume risk than patients on the 2.5 mg or 5 mg starting doses, though both groups need the medication held before elective anesthesia.

Talking to Your Surgical and Anesthesia Team

Disclosure is the single most important action a Zepbound patient can take before any procedure involving sedation or general anesthesia. Many pre-operative intake forms still do not list GLP-1 agonists by name. Patients need to be proactive.

What to Say, and to Whom

Tell every provider involved in your procedure that you take tirzepatide (Zepbound). This includes:

• The surgeon's office at the time of scheduling.
• The anesthesiologist during the pre-anesthesia interview.
• The pre-op nurse on the day of the procedure.

State the specific medication name, the dose, and the date of the last injection. Do not assume that because you told the surgeon's scheduler, the anesthesiologist knows. These systems are not always connected.

If You Forgot to Hold the Dose

Patients who realize on the day of surgery that they took their Zepbound dose within the past 7 days should tell their care team immediately. The anesthesiologist can then consider gastric ultrasound to assess residual stomach content and plan for rapid-sequence induction if needed. Concealing medication use to avoid procedure delays creates serious safety risk.

The ASA guidance notes explicitly that if GLP-1 agonist medication was not held and the procedure is elective, the team should consider postponing. [5] That is a medical judgment call, not a punishment.

Perioperative Aspiration Risk Management in Practice

Gastric Ultrasound as a Bedside Tool

Point-of-care gastric ultrasound is now performed at many academic and large community centers before anesthesia in patients with aspiration risk factors. A 2019 systematic review in the British Journal of Anaesthesia evaluated 18 studies and found that antral cross-sectional area measured by ultrasound reliably identifies patients with gastric volumes above 1.5 mL/kg, the threshold associated with aspiration risk. [8] Anesthesiologists familiar with this technique can use it to stratify risk in Zepbound patients who did not complete the medication hold.

Rapid-Sequence Induction

Rapid-sequence induction (RSI) is the standard anesthetic approach when aspiration risk is elevated. It involves pre-oxygenation, application of cricoid pressure, administration of a rapid-onset induction agent and a rapid-onset neuromuscular blocking drug (historically succinylcholine, increasingly rocuronium), and immediate laryngoscopy to place an endotracheal tube and secure the airway before the patient can vomit or regurgitate. RSI eliminates the mask-ventilation window during which aspiration is most likely.

If a patient on Zepbound must undergo emergency surgery, the anesthesiologist will typically proceed with RSI rather than a standard inhaled induction or propofol titration without airway protection. Telling the team about Zepbound use allows that plan to be made in advance rather than as an emergency response to vomiting at induction.

Antiemetic Prophylaxis and Post-Op Nausea

GLP-1 receptor agonist use is an independent risk factor for post-operative nausea and vomiting (PONV) independent of aspiration risk. A 2024 observational study in Anesthesia and Analgesia (N=4,265) found that patients on GLP-1 agonists had a statistically significant higher PONV rate post-operatively compared to matched controls not on GLP-1 therapy. [9] Anesthesiologists now include GLP-1 agonist use in PONV risk scoring and often administer multi-modal prophylaxis (ondansetron, dexamethasone, and sometimes scopolamine patches) to these patients.

When to Restart Zepbound After Surgery

Tirzepatide should not be restarted immediately after surgery. The reasons are both practical and physiological.

GI Recovery First

Surgical stress, opioid analgesia, and anesthetic agents all independently slow gastrointestinal motility in the post-operative period. Adding tirzepatide on top of this produces additive GI suppression and increases nausea, vomiting, and the risk of ileus. Patients should wait until:

• Normal bowel function has returned (passage of flatus or stool).
• Oral intake is tolerated without significant nausea.
• The prescribing clinician has reviewed the restart plan.

For most outpatient and short-stay procedures, this means restarting on the next scheduled weekly injection date, provided recovery is uncomplicated.

Major Abdominal Surgery

After major abdominal surgery, gastroparesis is a well-recognized complication affecting 10-50% of patients depending on the procedure. Restarting tirzepatide before gut motility is fully normalized could worsen this and delay recovery. In these cases, restart timing should be decided by the surgeon and the prescribing clinician together, often at the first post-operative visit.

Zepbound and Procedural Sedation (Colonoscopy, Endoscopy, Minor Procedures)

The aspiration risk is not limited to general anesthesia. Moderate sedation (formerly called "conscious sedation") used for colonoscopy, upper endoscopy, bronchoscopy, cardiac catheterization, and interventional radiology procedures also relies on airway-protective reflexes remaining intact. GLP-1-induced gastroparesis blunts those reflexes by increasing the volume of material available to regurgitate.

Gastroenterology societies have begun adapting their own pre-procedure guidance accordingly. A 2023 guidance document from the American Society for Gastrointestinal Endoscopy recommends that GLP-1 receptor agonist use be disclosed to the endoscopy team and that the same hold intervals applied by the ASA be considered for elective endoscopic procedures. [10]

If you are scheduled for a colonoscopy or upper endoscopy and you take Zepbound, apply the same one-week hold rule and the same disclosure requirements as for surgical anesthesia.

Special Populations: Diabetic Gastroparesis, Obesity, and Elevated Baseline Risk

Patients with type 2 diabetes already have a higher baseline prevalence of delayed gastric emptying. A large cross-sectional study in Diabetes Care (N=3,000+) found that 36% of patients with type 1 diabetes, 30% with type 2 diabetes, and 5% of healthy controls had delayed gastric emptying on scintigraphy. [11] Zepbound is approved for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related comorbidity; this population overlaps substantially with patients who have diabetes-associated gastroparesis.

For these patients, the already-delayed gastric emptying baseline compounds the tirzepatide-induced delay. Anesthesiologists should be told not just about the medication but also about any pre-existing gastroparesis symptoms: early satiety, bloating after meals, or a prior diagnosis.

Key Drug Interactions Beyond Aspiration Risk

Gastric emptying delay has a secondary consequence: it changes the absorption rate of oral medications taken the same day. Tirzepatide can reduce the peak plasma concentration (Cmax) of orally administered drugs that are absorbed in the small intestine, because gastric transit is the rate-limiting step for delivery to the duodenum.

The tirzepatide FDA label specifically notes that drugs dependent on threshold plasma concentrations for efficacy, such as oral contraceptives and certain anticoagulants, may be affected by tirzepatide co-administration. [4] Oral antibiotics given as surgical prophylaxis on the morning of a procedure may also be affected if the patient took tirzepatide recently, though the clinical significance of this specific interaction has not been fully studied.

Pre-operative oral medications should be reviewed with the anesthesiologist with Zepbound use in mind.